AtriCure falls despite solid Q4, 2018 prelims | Wall Street Beat

AtriCure (NSDQ:ATRC) shares took a fall today despite preliminary results for the fourth quarter and 2018 that topped estimates. The Mason, Ohio-based cardiac implant maker said it expects to post Q4 sales of $52.9 million and 2018 sales of $201.6 million, beating the consensus estimatyes on Wall Street for both periods. “We are pleased with our fourth quarter results and performance throughout 2018, as we continue our track record of strong, consistent revenue growth. We achieved many milestones and accomplishments in 2018: we completed enrollment in the Converge IDE trial, trained over 400 healthcare professionals worldwide, surpassed the 170,000 AtriClip milestone, launched the AtriClip FLEX•V device and established a dedicated pain management team,” president & CEO Mike Carrel said in prepared remarks. “We are well-positioned to continue executing on our strategy and positively impacting patient lives.” The company forecast 2019 sales of $220 million to $228 million. Investors reacted negatively to the news, sending ATRC shares down -4.3% to $29.89 apiece today in mid-afternoon trading. AxoGen plunges on prelims miss AxoGen Inc. (NSDQ:AXGN) missed expectations with its preliminary fourth-quarter and 2018 sales, sending its shares plunging this afternoon. The Alachua, Fla.-based peripheral nerve repair firm said it expects to report Q4 sales of $23.4 million and full-year revenues of $83.9 million, missing the consensus Wall Street estimates ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured MassDevice Earnings Roundup Wall Street Beat AtriCure Inc. AxoGen Cerus Corp. OrthoPediatrics Corp. Sientra STAAR Surgical Co Source Type: news